Simvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase blocker that is employed to treat hypercholesterolaemia and cardiovascular disorders, stimulated in vivo angiogenesis by promoting NO release through the assembly of the TRPV1-Akt-CaMKII-AMPK-eNOS complex described above (Su et al., 2014b). This evidence concerns the gene TRPV1 and Hypercholesterolemia.